Patient preferences for active ulcerative colitis treatments and fecal microbiota transplantation
- PMID: 38544906
- PMCID: PMC10966996
- DOI: 10.1177/20406223241239168
Patient preferences for active ulcerative colitis treatments and fecal microbiota transplantation
Abstract
Background: Fecal microbiota transplantation (FMT) is a promising treatment for active ulcerative colitis (UC). Understanding patient preferences can identify treatment features that may impact treatment decisions, improve shared decision-making, and contribute to patient-centered care, which is especially important in the context of novel treatments like FMT.
Objectives: We aimed to quantify preferences for active UC treatments, specifically FMT and biologics, and identify patient characteristics associated with different preference patterns.
Design: This is a cross-sectional survey study.
Methods: We administered a discrete choice experiment (DCE) survey to elicit preferences in a sample of Canadian adults with UC. DCE data were analyzed using a main-effects mixed logit model and used to predict uptake of hypothetical scenarios reflecting alternative combinations of treatment features. Latent class modeling identified heterogeneity in patient preference patterns.
Results: Participants' (n = 201) mean age was 47.1 years (SD: 14.5 years), 58% were female, and most (84%) had at least some post-secondary education. Almost half were willing to undergo FMT. When considering treatments for active UC, the most important attributes were chance of remission and severity of rare unknown side effects. All else equal, participants were most likely to uptake treatment that involves oral capsules/pills. Participants in the class with the highest utility for chance of remission were younger, had more severe disease, and 58% indicated that they would be willing to undergo FMT.
Conclusion: We identified characteristics of UC patients who are more likely to be interested in FMT using preference elicitation methods. Patient-centered care can be enhanced by knowing which patients are more likely to be interested in FMT, potentially improving satisfaction with and adherence to treatments for active UC to maximize the effectiveness of treatment while considering heterogeneity in patient preferences.
Keywords: fecal microbiota transplantation; patient preferences; ulcerative colitis.
Plain language summary
Patient preferences for active ulcerative colitis treatments and fecal microbiota transplantation.
Background and aims: Fecal microbiota transplantation (FMT) is a promising new treatment for active ulcerative colitis. Questions remain around the benefits and risks of FMT treatment for patients with ulcerative colitis. Understanding how patients weigh the treatment features and how treatment features influence their decisions may improve shared decision-making and contribute to patient-centered care, which is especially important for novel treatments like FMT.Using an experimentally designed survey, we aimed to:1. Elicit patient preferences for features of active ulcerative colitis treatments, specifically FMT and biologics; and,2. Identify patient characteristics associated with different preference patterns.
Results: We found that younger patients with more severe disease are more likely to try FMT for the treatment of active ulcerative colitis. Oral capsules/pills are the preferred mode of treatment administration.
Conclusions: These findings can enhance patient-centered care by characterizing patients who are more likely to be interested in FMT. Aligning treatment with the features that are important to patients can potentially improve satisfaction with and adherence to treatments for active ulcerative colitis to maximize their effectiveness for individual patients.
© The Author(s), 2024.
Figures


Similar articles
-
Patient preferences and current practice for adults with steroid-resistant ulcerative colitis: POPSTER mixed-methods study.Health Technol Assess. 2022 Oct;26(41):1-118. doi: 10.3310/RHXR5192. Health Technol Assess. 2022. PMID: 36305390 Free PMC article.
-
Perception of fecal microbiota transplantation in patients with ulcerative colitis in Korea: a KASID multicenter study.Korean J Intern Med. 2024 Sep;39(5):783-792. doi: 10.3904/kjim.2024.053. Epub 2024 Aug 30. Korean J Intern Med. 2024. PMID: 39252488 Free PMC article.
-
Capsulized Fecal Microbiota Transplantation Induces Remission in Patients with Ulcerative Colitis by Gut Microbial Colonization and Metabolite Regulation.Microbiol Spectr. 2023 Jun 15;11(3):e0415222. doi: 10.1128/spectrum.04152-22. Epub 2023 Apr 24. Microbiol Spectr. 2023. PMID: 37093057 Free PMC article. Clinical Trial.
-
Fecal transplantation for treatment of inflammatory bowel disease.Cochrane Database Syst Rev. 2018 Nov 13;11(11):CD012774. doi: 10.1002/14651858.CD012774.pub2. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2023 Apr 25;4:CD012774. doi: 10.1002/14651858.CD012774.pub3. PMID: 30480772 Free PMC article. Updated.
-
Fecal microbiota transplantation in ulcerative colitis.Acta Gastroenterol Belg. 2019 Oct-Dec;82(4):519-528. Acta Gastroenterol Belg. 2019. PMID: 31950808 Review.
References
-
- Turner D, Ricciuto A, Lewis A, et al.. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 2021; 160: 1570–1583. - PubMed
-
- Rubin DT, Ananthakrishnan AN, Siegel CA, et al.. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol 2019; 114: 384–413. - PubMed
-
- Kassam Z, Lee CH, Yuan Y, et al.. Fecal microbiota transplantation for clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 2013; 108: 500–508. - PubMed
-
- Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of clostridium difficile infection: a systematic review. J Clin Gastroenterol 2014; 48: 693–702. - PubMed
LinkOut - more resources
Full Text Sources